Holen Sie sich die Stockscreener-App
67.83
0.68%
-0.335
Schlusskurs vom Vortag:
$68.17
Offen:
$68.16
24-Stunden-Volumen:
82,892
Relative Volume:
0.14
Marktkapitalisierung:
$2.89B
Einnahmen:
$451.36M
Nettoeinkommen (Verlust:
$-66.42M
KGV:
-42.14
EPS:
-1.6097
Netto-Cashflow:
$-22.31M
1W Leistung:
-7.58%
1M Leistung:
+11.40%
6M Leistung:
+37.17%
1J Leistung:
+45.70%
1-Tages-Spanne:
$67.61
$69.09
1-Wochen-Bereich:
$67.43
$75.20
52-Wochen-Spanne:
$38.51
$85.25
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Firmenname
Tarsus Pharmaceuticals Inc
Sektor
Branche
Telefon
(949) 409-9820
Adresse
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
67.84 | 2.90B | 451.36M | -66.42M | -22.31M | -1.6097 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.28 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.73 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
695.77 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.53 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.50 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-11-20 | Eingeleitet | Mizuho | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-11-20 | Eingeleitet | Goldman | Neutral |
| 2023-07-18 | Eingeleitet | William Blair | Outperform |
| 2023-05-18 | Eingeleitet | Guggenheim | Buy |
| 2022-08-01 | Eingeleitet | Barclays | Overweight |
| 2021-12-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-23 | Eingeleitet | Oppenheimer | Outperform |
| 2020-11-10 | Eingeleitet | BofA Securities | Buy |
| 2020-11-10 | Eingeleitet | Jefferies | Buy |
| 2020-11-10 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-11-10 | Eingeleitet | Raymond James | Strong Buy |
Alle ansehen
Tarsus Pharmaceuticals Inc Aktie (TARS) Neueste Nachrichten
Tarsus Pharmaceuticals at Barclays Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 6.1%Should You Sell? - MarketBeat
Quantbot Technologies LP Reduces Holdings in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
(TARS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Jefferies Financial Group Inc. - MarketBeat
Tarsus Pharmaceuticals Bets Big on XDEMVY Growth - TipRanks
Tarsus Reports Soaring Xdemvy Sales in Q4, Full Year - Orange County Business Journal
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Mixed Share Performance - Yahoo Finance
Citigroup Inc. Increases Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
XDEMVY Growth And China Deal Reshape Tarsus Pharmaceuticals Investment Story - Sahm
What dividend safety score for Tarsus Pharmaceuticals Inc. stockDividend Hike & AI Powered Market Trend Analysis - Naître et grandir
Aug Gainers: Why is Tarsus Pharmaceuticals Inc stock going downPortfolio Update Summary & Stock Timing and Entry Methods - baoquankhu1.vn
FOMO Trade: Will Tarsus Pharmaceuticals Inc benefit from rising consumer demand2025 Performance Recap & Low Risk Growth Stock Ideas - baoquankhu1.vn
Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating - Yahoo Finance
Tarsus Pharma COO Neervannan Seshadri sells $641k in stock By Investing.com - Investing.com Australia
Tarsus Pharma COO Neervannan Seshadri sells $641k in stock - Investing.com India
10 Fastest Growing NASDAQ Stocks to Buy - Insider Monkey
[144] Tarsus Pharmaceuticals, Inc. SEC Filing - Stock Titan
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Vanguard Group Inc. - MarketBeat
Tarsus Pharmaceuticals at TD Cowen Conference: Eyeing Blockbuster Growth By Investing.com - Investing.com Canada
TARS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
A Look At Tarsus Pharmaceuticals (TARS) Valuation After 2025 Results And New Shelf Registration - Sahm
Tarsus Pharmaceuticals (TARS) Stock Analysis: Strong Buy Ratings and 21.88% Upside Potential - DirectorsTalk Interviews
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Passes High-Growth Momentum and Minervini Trend Template Screen - ChartMill
Aug PreEarnings: Why is Oak Woods Acquisition Corporation Equity Right stock going upWeekly Trade Recap & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Artisan Partners Limited Partnership Boosts Stock Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
(TARS) Risk Channels and Responsive Allocation - Stock Traders Daily
Tarsus Pharmaceuticals (NASDAQ:TARS) Downgraded to Hold Rating by Zacks Research - MarketBeat
Tarsus to Participate in Upcoming Investor Conferences - Bitget
HC Wainwright Brokers Decrease Earnings Estimates for TARS - MarketBeat
Tarsus Pharmaceuticals (TARS) Is Up 14.8% After XDEMVY-Fueled Revenue Surge and New Equity Shelf Filing - simplywall.st
Has The Market Rerated Tarsus Pharmaceuticals (TARS) Too Cautiously After XDEMVY Adoption Headlines? - Yahoo Finance
Tarsus Pharmaceuticals (TARS) Receives Analyst Rating Upgrade fr - GuruFocus
Tarsus Pharmaceuticals (NASDAQ:TARS) Given New $105.00 Price Target at Oppenheimer - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $90.00 at Guggenheim - MarketBeat
TARS: Guggenheim Raises Price Target to $90, Maintains Buy Ratin - GuruFocus
Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $105 From $95, Maintains Outperform Rating - marketscreener.com
Analysts Offer Predictions for TARS FY2030 Earnings - MarketBeat
Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis: Healthcare Innovator with 32.92% Potential Upside - DirectorsTalk Interviews
Tarsus Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - VisionMonday.com
Tarsus Pharmaceuticals (TARS) Narrowing EPS Loss Backs Bullish Earnings Turnaround Narrative - simplywall.st
Tarsus Pharmaceuticals: Q4 Results Highlight Xdemvy Blockbuster Potential (NASDAQ:TARS) - Seeking Alpha
Tarsus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap UpTime to Buy? - MarketBeat
Tarsus Pharmaceuticals (TARS) Shares Surge Over 11% - GuruFocus
Tarsus Pharmaceuticals Q4 2025 Earnings Call Highlights - Intellectia AI
Tarsus Pharma's XDEMVY Sales Soar 150% In FY25, Peak Sales Potential To Exceed $2Bln - RTTNews
Earnings call transcript: Tarsus Pharmaceuticals Q4 2025 sees robust growth By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals, Inc. (TARS) reports Q4 loss, beats revenue estimates - MSN
Decoding Tarsus Pharmaceuticals Inc (TARS): A Strategic SWOT Ins - GuruFocus
Finanzdaten der Tarsus Pharmaceuticals Inc-Aktie (TARS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):